ANI Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for ANI Pharmaceuticals (ANIP).

Price Target Range — 11 Quarters

Analyst Consensus — 11 Analysts

9Buy

2Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$94Upside to Avg. PT+32.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Perform	$85
Aug 10, 2026	Guggenheim	Vamil Divan	PT Cut	Buy	$124→$119
Aug 10, 2026	Canaccord Genuity	Gary Nachman	PT Cut	Hold	$91→$90
Jul 17, 2026	Canaccord Genuity	Gary Nachman	Initiate	Hold	$91
Jul 10, 2026	Guggenheim	Vamil Divan	Maintained	Buy	$124
Jan 16, 2026	Guggenheim	Vamil Divan	PT Raise	Buy	$115→$124
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Overweight	$100
Nov 10, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$114→$115
Oct 9, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$77→$90
Sep 24, 2025	JP Morgan	Ekaterina Knyazkova	PT Raise	Overweight	$95→$115
Sep 17, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$93→$121
Sep 8, 2025	Guggenheim	Vamil Divan	PT Raise	Buy	$86→$114
Aug 11, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$65→$77
Aug 8, 2025	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$84→$93
Jul 10, 2025	HC Wainwright & Co.	Brandon Folkes	Initiate	Buy	$84
May 12, 2025	Guggenheim	Vamil Divan	Maintained	Buy	$86
Apr 21, 2025	Truist Securities	Gregory Fraser	PT Raise	Hold	$62→$65
Apr 11, 2025	Guggenheim	Vamil Divan	Maintained	Buy	$86
Mar 17, 2025	HC Wainwright & Co.	Oren Livnat	Maintained	Buy	$94
Mar 14, 2025	Jefferies	Glen Santangelo	Initiate	Buy	$80

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

Oppenheimer analyst Les Sulewski initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Perform rating and announces Price Target of $85.

Benzinga Newsdesk

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported strong Q2 earnings, affirmed FY2026 guidance, and saw changes in price targets by analysts.

Avi Kapoor

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.

Benzinga Newsdesk

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

Canaccord Genuity analyst Gary Nachman initiates coverage on ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold rating and announces Price Target of $91.

Benzinga Newsdesk

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

Guggenheim analyst Vamil Divan reiterates ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and maintains $124 price target.

Benzinga Newsdesk

ANI Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

ANI Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

People Also Watch

People Also Watch

ANI Pharmaceuticals Inc

ニュース

パートナーシップ

ベンジンガ・グローバル

ANI Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROOppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

These Analysts Slash Their Forecasts On ANI Pharmaceuticals After Q2 Results

PROGuggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PROCanaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PROCanaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PROGuggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

People Also Watch

People Also Watch

PRO
Oppenheimer Initiates Coverage On ANI Pharmaceuticals with Perform Rating, Announces Price Target of $85

PRO
Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119

PRO
Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

PRO
Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

PRO
Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target